The influence of doxycycline on articular cartilage in experimental osteoarthrosis induced by iodoacetate

• Autorzy: Cylwik J , Kita K. , Barwijuk-Machala M. , Reszec J. , Klimiuk P. , Sierakowski S. , Sulkowski S.
• Języki publikacji: EN

Abstrakty

EN

The experiment was performed on 36 Wistar rats. On the first day of the experiment iodoacetate was administered to the left posterior knee joint of the 18 rats which composed Group I. The second group of 18 rats received additionally doxycycline (doxy) through the gastric tube in doses comparable with those of doxycycline used in humans. The experiment lasted 21 days. The animals were sacrificed after 7, 14 and 21 days in groups of 6 rats each. In sections stained with Safranin 0 semiquantitative histochemical intensity tests were performed on articular cartilage glycosaminoglycans (GAG) using a four-point scale (0–3). In the first group examined destructive lesions in the articular cartilage and weak reactivity on GAG were noted at all stages of the experiment. The intensity of GAG staining was higher in the second group after 14 and especially after 21 days, which may suggest a protective action of doxy on articular cartilage.

Słowa kluczowe

EN

degenerative disease; Wistar rat; osteoarthrosis; joint; doxycycline; rat; iodoacetate

• Wydawca: -
• Czasopismo: Folia Morphologica
• Rocznik: 2004
• Tom: 63
• Numer: 2
• Opis fizyczny: p.237-239,ref.

Twórcy

autor

Cylwik J

• Medical Academy, Waszyngtona 13, 15-269 Bialystok, Poland

autor

Kita K.

autor

Barwijuk-Machala M.

autor

Reszec J.

autor

Klimiuk P.

autor

Sierakowski S.

autor

Sulkowski S.

Bibliografia

• 1. Poole AR, Rizkalla G, Jonescu M, Reiner A, Brooks E, Rorabeck C, Bourne R, Bogoch E (1993) Osteoarthritis in the human knee: a dynamic process of cartilage matrix degradation, synthesis and reorganisation. Agents Actions, 39 (suppl.): 3–13.
• 2. Lohmander LS, Hoerrner LA, Larh MW (1996) Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum, 36: 181–189.
• 3. Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ (1996) Cloning, expression and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest, 97: 761–768.
• 4. Martel J (1996) Wanted-the collagenase responsible for the destruction of the collagen network in human cartilage. Br J Rheumatol, 35: 818.
• 5. Pelletier J (1997) Etiopathogenesis of osteoarthritis. In: Koopman (ed.). Arthritis and allied conditions. A textbook of rheumatology. Williams and Wilkins. Baltimore.
• 6. Whittaker M, Floyd CD, Brown P, Gearing AJH (1999) Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev, 99: 2735–2776.
• 7. Janun MJ, Hookfin EB, Heitmeyer SA, Woessner JF, Freemont AJ, Hoyland JA, Brown KK, Hsieh LC, Almstead NG, De B, Natchus MG, Pikul S, Taiwo YO (2001) Moderation of iodoacetate- induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors. Osteoarthritis and Cartilage, 9: 751–760.
• 8. Yu LP Jr, Smith GN Jr, Brandt KD, Myers SL, O’Connor BL, Brandt DA (1992) Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline. Arthritis Rheum, 35: 1150–1159.
• 9. De Bri E, Lei W, Svensson O, Chowdhury M, Moak SA, Greenwald RA (1998) Effect of an inhibitor of matrix metalloproteinases on spontaneous osteoarthritis in guinea pigs. Adv Dent Res, 12: 82–85.
• 10. Guingamp C, Gegout-Pottie P, Philippe L, Terlain B, Netter P, Gillet P (1997) Mono-iodoacetate-induced experimental osteoarthritis. A dose-response study of loss of mobility, morphology, and biochemistry. Arthritis Rheum, 40: 1670–1679.